Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?
AI-Driven “TechBio” Strategy Recursion’s narrative centers on its AI-enhanced drug discovery platform. Founded in 2013 in Salt Lake City, Recursion has spent years building RecursionOS, a giant database of cellular images and chemical data powered by machine learning biotechhealthx.com. The company invested heavily in bio-automation infrastructure (like its NVIDIA-based supercomputers) to train AI models on billions of data points. Its strategy is twofold: use this tech to generate proprietary drug candidates while partnering with pharma giants to co-develop new drugs. As one biotech newsletter notes, Recursion “has focused on fewer but more strategically important deals” with big pharma, securing hefty